AMGN Amgen Inc.

Mentions (70)

• News (RSS)zerohedge·1d ago·Neutral

  … asked. ZeroHedge detailed the fight over the review in May. Still on sale Tavneos is still on sale in the US, five months after Høeg's drug center moved to pull it. Amgen's pill for a rare autoimmune disease of the blood vessels was approved in 2021 on the strength of a single pivotal trial. The FDA had told its developer that the trial had to show the drug beat steroids at 52 weeks. In January, the FDA asked Amgen to withdraw it voluntarily. Amgen declined. In April, the agency formally propos…

  View source ↗
• News (RSS)fool·1d ago·Positive

  Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential.

  View source ↗
• Newsfool.com·1d ago·Positive

  Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? Amgen offers a diversified portfolio of established therapies across oncology and inflammation supported by robust cash flow. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market and is expanding into high-growth gene therapies.

  View source ↗
• News (RSS)seekingalpha·2d ago·Neutral

  AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

  View source ↗
• Newszacks.com·4d ago·Positive

  Amgen (AMGN) Stock Dips While Market Gains: Key Facts Amgen (AMGN) closed at $407.27 in the latest trading session, marking a -3.38% move from the prior day.

  View source ↗
• Newszacks.com·4d ago·Negative

  Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.

  View source ↗
• News (Marketaux)gurufocus.com·6d ago·Positive

  Amgen Inc (AMGN) Shares Surge 1.3% -- What GF Score of 87 Tells Investors On September 29, 2026, Amgen <e[+239 characters]

  View source ↗
• News247wallst.com·7d ago·Negative

  Why Amgen's 6% Dividend Raise Masks a Tougher Road Ahead Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.

  View source ↗
• Newsfool.com·9d ago·Neutral

  2 Healthcare Stocks That Just Delivered Great News for Investors Vertex Pharmaceuticals and Amgen recently posted strong clinical trial results for promising candidates. Both companies have robust businesses and strong medium-term prospects.

  View source ↗
• Newszacks.com·10d ago·Neutral

  Amgen (AMGN) Rises Higher Than Market: Key Facts In the latest trading session, Amgen (AMGN) closed at $414.61, marking a +2.11% move from the previous day.

  View source ↗
• Newszacks.com·10d ago·Neutral

  Bet on These 5 Dividend Growth Stocks Amid Rising Treasury Yields Rising Treasury yields are reshaping market preferences, putting dividend growth stocks like EnerSys and Amgen in focus for income and growth.

  View source ↗
• Newszacks.com·11d ago·Neutral

  Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

  View source ↗
• Newsproactiveinvestors.com·12d ago·Negative

  Amgen price target raised by Jefferies to $410 after positive Sjögren's data Amgen Inc (NASDAQ:AMGN, XETRA:AMG)'s price target was raised to $410 from $367 by Jefferies after dazodalibep delivered positive Phase 3 results in patients with systemic Sjögren's disease. Jefferies said the drug, a CD40L antagonist, achieved a statistically significant and clinically meaningful improvement in the primary endpoint, the change from baseline in ESSDAI at week 48.

  View source ↗
• Newszacks.com·12d ago·Neutral

  AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.

  View source ↗
• News (RSS)investing·13d ago·Neutral

  Amgen, Vicor among market cap stock movers on Tuesday

  View source ↗
• Newsbenzinga.com·13d ago·Neutral

  Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data Amgen Inc. (NASDAQ:AMGN) has reported encouraging topline outcomes from its Phase 3 OASIZ 301 study. The trial assessed the efficacy of dazodalibep in adult patients suffering from Sjögren's disease accompanied by moderate-to-severe systemic disease activity.

  View source ↗
• Newsreuters.com·14d ago·Negative

  Amgen's autoimmune drug succeeds in late-stage trial Amgen said on Tuesday its experimental drug to treat an autoimmune ​disease that attacks the body's moisture-producing ‌glands met the main goal of reducing disease activity in a late-stage trial.

  View source ↗
• Newsprnewswire.com·14d ago·Neutral

  … Highly Differentiated Treatment Option for People Living With a Debilitating Autoimmune Disease  THOUSAND OAKS, Calif., Sept. 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity.

  View source ↗
• News (RSS)thestreet·14d ago·Negative

  Morgan Stanley flags Amgen's edge after heart-drug rival stumbles A private meeting with Amgen management left Morgan Stanley with a very different read than the broader market's.

  View source ↗
• Newszacks.com·14d ago·Positive

  Veeva Expands Amgen Partnership With Global Vault CRM Rollout Plan VEEV expands its decade-long Amgen partnership with a global Vault CRM rollout, reinforcing enterprise adoption and commercial subscription growth.

  View source ↗
• News (Marketaux)finance.yahoo.com·16d ago·Positive

  Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story? Quick Read Amgen (AMGN) yields[+291 characters]

  View source ↗
• News247wallst.com·17d ago·Negative

  Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story? Both Amgen and Merck write quarterly checks and raise them every year, but only one has the portfolio depth to keep growing that payout through the next brutal round of patent expirations.

  View source ↗
• Newszacks.com·17d ago·Neutral

  Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing In the most recent trading session, Amgen (AMGN) closed at $385.65, indicating a +1.55% shift from the previous trading day.

  View source ↗
• Newsmarketbeat.com·20d ago·Neutral

  Amgen Highlights MariTide, IMDELLTRA Pipeline Progress and Growth Priorities Amgen NASDAQ: AMGN outlined its growth priorities, late-stage pipeline progress and capital-allocation framework during a Morgan Stanley conference, as newly appointed Chief Financial Officer Thomas Dittrich emphasized execution, financial discipline and cash-on-cash returns.

  View source ↗
• News (RSS)seekingalpha·20d ago·Positive

  Amgen Inc. (AMGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  View source ↗
• Newsseekingalpha.com·20d ago·Positive

  Amgen Inc. (AMGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Amgen Inc. (AMGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  View source ↗
• Newszacks.com·22d ago·Neutral

  Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

  View source ↗
• Newszacks.com·22d ago·Neutral

  4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike AMGN, BHC, CDNA and CNC offer defensive healthcare plays as inflation climbs and the Fed readies for a possible rate hike.

  View source ↗
• News (Marketaux)finance.yahoo.com·22d ago·Neutral

  Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. Why Lilly's stock didn't drop much [+313 characters]

  View source ↗
• News (Marketaux)finance.yahoo.com·22d ago·Negative

  Amgen (AMGN) Fell 5% on a Drug That Isn’t Even Its Own. Here’s the Lp(a) Bet Now in Question. Amgen Inc. (NASDAQ[+317 characters]

  View source ↗
• News (RSS)seekingalpha·22d ago·Neutral

  Notable healthcare headlines for the week: UnitedHealth, Amgen, and CooperCompanies in focus

  View source ↗
• News (RSS)yahoo·23d ago·Neutral

  Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure

  View source ↗
• Newsmarketbeat.com·24d ago·Neutral

  Amgen Highlights 26% Growth Drivers, IMDELLTRA Momentum and MariTide Potential Amgen NASDAQ: AMGN executives highlighted growth across its key commercial products, progress in late-stage development programs and a continued focus on profitability and cash returns during a Wells Fargo biotech and pharma discussion.

  View source ↗
• Newsmarketbeat.com·24d ago·Neutral

  Amgen Drops 10% on a Trial It Didn't Even Run Amgen TodayAMGNAmgen$379.72 -2.75 (-0.72%) As of 12:05 PM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$269.77▼$447.03Dividend Yield2.65%P/E Ratio23.61Price Target$381.68Add to WatchlistAmgen Inc. NASDAQ: AMGN delivered a strong earnings report on Aug. 4.

  View source ↗
• Newszacks.com·24d ago·Negative

  Are Medical Stocks Lagging Amgen (AMGN) This Year? Here is how Amgen (AMGN) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.

  View source ↗
• Newszacks.com·25d ago·Neutral

  Amgen (AMGN) Dips More Than Broader Market: What You Should Know The latest trading day saw Amgen (AMGN) settling at $382.47, representing a -2.25% change from its previous close.

  View source ↗
• News (RSS)fool·25d ago·Positive

  Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026? Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.

  View source ↗
• Newszacks.com·25d ago·Negative

  AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study Amgen and AstraZeneca's Imdelltra-Imfinzi combo shows survival benefits in first-line ES-SCLC, potentially broadening both drugs' reach.

  View source ↗
• News (Marketaux)gurufocus.com·25d ago·Positive

  AMGN Looks 6.9% Overvalued on GF Value™ as Dividend Sustainability Remains Strong On September 10, 2026, HSBC analyst Mort[+321 characters]

  View source ↗
• Newsseekingalpha.com·26d ago·Positive

  Amgen: Buy The Novartis-Driven Selloff (Rating Upgrade) Amgen is upgraded to a buy rating, reflecting strengthened fundamentals and a robust long-term growth outlook. Q2 saw a significant growth rebound, with 22 products posting at least double-digit sales growth and key drivers like Tezspire and Repatha accelerating. Profitability remains respectable despite cost of sales pressures; AMGN raised full-year 2026 revenue and EPS guidance, signaling improved confidence.

  View source ↗
• Newsprnewswire.com·26d ago·Neutral

  AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE THOUSAND OAKS, Calif., Sept. 9, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 24th Annual Global Healthcare Conference at 11:30 a.m.

  View source ↗
• News (RSS)investing·27d ago·Neutral

  Amgen and AstraZeneca report positive lung cancer trial results

  View source ↗
• News (RSS)yahoo·27d ago·Negative

  Why Novartis’ Drug Trial Results Are Blowing Up Amgen Stock

  View source ↗
• News247wallst.com·27d ago·Negative

  Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14% A failed cholesterol trial from Novartis (NYSE:NVS | NVS Price Prediction) is dragging the Lp(a) drug class lower and hitting Amgen (NASDAQ:AMGN) harder than any large-cap peer in Tuesday trading.

  View source ↗
• News (RSS)zerohedge·27d ago·Negative

  …26 results. Herbalife (HLF) rises 7% after the maker of dietary supplements announced a $250 million share buyback. Ionis Pharmaceuticals (IONS) falls 10% and Amgen (AMGN) slumps 5% after Novartis AG said its heart medication, pelacarsen, failed in a final-stage study. Pharvaris (PHVS) soars 25% after a Phase 3 trial of its deucrictibant extended-release tablet for the prevention of hereditary angioedema attacks met its primary and secondary endpoints. Rigetti Computing (RGTI) rises 5% after the…

  View source ↗
• News (RSS)yahoo·27d ago·Positive

  Here Are Tuesday’s Top Wall Street Analyst Research Calls: Amgen, Baidu, Best Buy, Circle Internet, Corning, Intel, Lockheed Martin SpaceX, TeraWulf and More

  View source ↗
• News (RSS)investing·27d ago·Neutral

  BMO lowers Amgen, BioNTech to Market Perform as risk-reward shifts

  View source ↗
• Newszacks.com·28d ago·Positive

  Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key stock portfolios.

  View source ↗
• News (RSS)barrons·28d ago·Neutral

  Stock Market Today: Dow Drops, Oil Nears $100 Amgen drop hurts health-care sector; Brent crude climbs after Houthi attacks

  View source ↗
• Newsbarrons.com·28d ago·Negative

  Why Amgen Stock Is Dropping After Swiss Rival's Trial Setback Big Pharma has been scrambling to restock its pipelines, so a disappointing readout can have a knock-on effect on other drugmakers.

  View source ↗
• Newscnbc.com·28d ago·Negative

  Cholesterol drug setback casts doubt over multibillion-dollar race Novartis' pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.

  View source ↗
• Newszacks.com·28d ago·Negative

  Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal AMGN shares fall as NVS' pelacarsen setback casts investor concern over whether olpasiran can deliver positive phase III outcome data.

  View source ↗
• Newszacks.com·28d ago·Positive

  Why Amgen (AMGN) is a Top Growth Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

  View source ↗
• Newszacks.com·32d ago·Neutral

  AMGN's MariTide: Can Convenience Drive its Obesity Market Share? Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifies.

  View source ↗
• Newsprnewswire.com·33d ago·Neutral

  AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE THOUSAND OAKS, Calif., Sept. 2, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m.

  View source ↗
• News (Marketaux)gurufocus.com·35d ago·Positive

  AMGN Looks 18.3% Overvalued on GF Value™ as Dividend Sustainability Remains Solid On August 31, 2026, Amgen I[+256 characters]

  View source ↗
• Newsprnewswire.com·36d ago·Neutral

  …d Management, With Many High-Risk Patients Undertreated and Not Achieving Recommended LDL-C Goals THOUSAND OAKS, Calif., Aug. 31, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new findings showing Repatha® (evolocumab) reduced the risk of death in high-risk adults without a prior heart attack or stroke when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments.

  View source ↗
• Newsinvestors.com·36d ago·Neutral

  One Of Amgen's Biggest Moneymakers Cuts The Risk Of Dying By 20% Amgen said Monday its cholesterol buster, Repatha, reduced the risk of death by 20% in a study of more than 12,000 high-risk patients.

  View source ↗
• News (RSS)yahoo·37d ago·Positive

  Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

  View source ↗
• Newsfool.com·37d ago·Positive

  Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? Amgen is a diversified pharmaceutical giant with high net margins. It reported nearly $8.1 billion in free cash flow for fiscal 2025.

  View source ↗
• Newsdefenseworld.net·38d ago·Positive

  Biotech Stocks To Watch Today – August 27th Moderna, Revolution Medicines, and Amgen are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that develop products or technologies based on biology, such as pharmaceuticals, vaccines, medical treatments, diagnostics, and genetic therapies. For investors, these stocks can offer significant growth potential but

  View source ↗
• Newsprnewswire.com·40d ago·Negative

  …52 Efficacy in a Third Epithelial-Driven Inflammatory Disease Supports Broad Potential of TEZSPIRE THOUSAND OAKS, Calif., Aug. 27, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE® (tezepelumab-ekko) in patients living with eosinophilic esophagitis (EoE).

  View source ↗
• Newszacks.com·42d ago·Neutral

  Amgen Touches 52-Week High: Buy, Sell or Hold the Stock? AMGN's strong growth drivers and promising pipeline support long-term growth, but patent losses, pricing pressure and valuation warrant caution.

  View source ↗
• Newszacks.com·45d ago·Positive

  Here's Why Amgen (AMGN) is a Strong Momentum Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

  View source ↗
• Newszacks.com·46d ago·Neutral

  Bet on These Biotech ETFs as Innovation Drives Market-Beating Growth Biotech ETFs are riding a powerful rally fueled by innovation, obesity drugs and M&A, with three funds offering diversified exposure to growth.

  View source ↗
• News (RSS)investing·48d ago·Neutral

  Amgen stock hits all-time high at 422.49 USD

  View source ↗
• Newszacks.com·49d ago·Positive

  Here's Why Amgen (AMGN) is a Strong Growth Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

  View source ↗
• News247wallst.com·52d ago·Neutral

  5 Safe High-Yield Stocks Boomers Should Own in August Baby Boomers building retirement income want two things from a dividend stock: a check that shows up on schedule, and a balance sheet that says the check will still show up ten years from now.

  View source ↗
• 4chan /biz/biz·54d ago·Positive

  Do you know about the HALO trade? Heavy Assets Low Obsolescence HALO It's become basically the counter AI trade. HALO companies are companies with high capital costs, and heavy assets. And big moats. Like a manufacturing company, like Ford or some s***, or Walmart. It's had a low correlation with the AI trade. There's some new HALO etfs, but they have like 70 bps fees or some s***. I'll show you a HALO ETF with dirt cheap fees. SCHD. It's not a perfect HALO tracker but it's like 90% there. A

  View source ↗
• News (Marketaux)insidermonkey.com·56d ago·Positive

  Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY He said: Amgen just racked up [+307 characters]

  View source ↗